Criterion Validation Testing of Clinical Metrology Instruments for Measuring Degenerative Joint Disease Associated Mobility Impairment in Cats

摘要: Introduction Degenerative joint disease and associated pain are common in cats, particularly older cats. There is a need for treatment options, however evaluation of putative therapies limited by lack suitable, validated outcome measures that can be used the target population client owned The objectives this study were to evaluate low-dose daily meloxicam with degenerative further validate two clinical metrology instruments, Feline Musculoskeletal Pain Index (FMPI) Client Specific Outcome Measures (CSOM). Methods Sixty-six cats owner-reported impairments mobility screened enrolled into double-masked, placebo-controlled, randomized trial. Following run-in baseline period, given either placebo or 21 days, then masked washout, all days. Subsequently, opposite treatment, meloxicam, Cats wore activity monitors throughout study, owners completed instruments following each period. Results Activity counts increased during (p<0.0001) compared baseline. FMPI results count data offer concurrent validation FMPI, though relationship between scores at was poor (R2=0.034). CSOM did not show responsiveness improvement similarly (R2=0.042). Conclusions Refinements including abbreviation instrument scoring as percent possible score recommended. This offered use detecting therapeutic efficacy disease.